| Literature DB >> 32545600 |
Michał Stasiowski1, Anna Duława2, Izabela Szumera1, Radosław Marciniak1, Ewa Niewiadomska3, Wojciech Kaspera4, Lech Krawczyk1, Piotr Ładziński4, Beniamin Oskar Grabarek5,6, Przemysław Jałowiecki1.
Abstract
BACKGROUND AND OBJECTIVES: Raw electroencephalographic (EEG) signals are rarely used to monitor the depth of volatile induction of general anaesthesia (VIGA) with sevoflurane, even though EEG-based indices may show aberrant values. We aimed to identify whether response (RE) and state entropy (SE) variations reliably reflect the actual depth of general anaesthesia in the presence of different types of epileptiform patterns (EPs) in EEGs during induction of general anaesthesia.Entities:
Keywords: epileptiform EEG patterns; periodic epileptiform discharges; polyspikes; response entropy; rhythmic polyspikes; sevoflurane; state entropy
Year: 2020 PMID: 32545600 PMCID: PMC7349226 DOI: 10.3390/brainsci10060366
Source DB: PubMed Journal: Brain Sci ISSN: 2076-3425
Comparison of values of monitored patients’ parameters at the same stage between studied groups (stage 1—before onset of VIGA, stage 2—after LOC, stage 3—before presence of first epileptiform pattern, stage 4—during presence of epileptiform patterns, stage 5—during the highest values of RE and RE during presence of epileptiform patterns in patients from group VIMA and VCRII, Stage 6—during the highest values of RE and RE after disappearance of epileptiform patterns in patients from groups VIMA and VCRII).
| Induction | VIMA-EP | VCRII-EP | VIMA-nEP | VCRII-nEP | ||
|---|---|---|---|---|---|---|
| Level | Parameters | |||||
| STAGE 1 | SE START | 88.8 ± 1.6 | 88.1 ± 1.8 | 89.3 ± 0.8 | 88.3 ± 1 | |
| RE START | 97.7 ± 1.3 | 98.3 ± 0.8 | 98.5 ± 0.8 | 98.4 ± 0.7 | ||
| STAGE 2 | SE DURING LOC | 85 ± 4.7 | 85.9 ± 4.9 | 85.8 ± 2 | 88.2 ± 1.9 | |
| RE DURING LOC | 95.5 ± 3.9 | 95.9 ± 4.1 | 96.3 ± 2.9 | 96.8 ± 2.2 | ||
| STAGE 3 | SE BEFORE EP | 26.1 ± 14.5 | 53.4 ± 39.1 | 61 ± 29.8 | 82.1 ± 9.6 | |
| RE BEFORE EP | 30 ± 20 | 59.1 ± 44 | 67.2 ± 33.3 | 90 ± 10 | ||
| STAGE 4 | SE ONSET OF EP | 24 ± 11.7 | 46.9 ± 38.4 | 22.5 ± 6 | 15.1 ± 5.8 | |
| RE ONSET OF EP | 29 ± 16 | 53.4 ± 41.4 | 24.5 ± 5 | 17.7 ± 7.8 | ||
| STAGE 5 | SE DURING EP | 30 ± 20.1 | 10.9 ± 3.3 | 27 ± 6.7 | 18.6 ± 5.6 | |
| RE DURING EP | 35.9 ± 24.3 | 12.3 ± 3.5 | 29 ± 7 | 19.6 ± 6.4 | ||
| STAGE 6 | SE AFTER EP | 24.1 ± 11.2 | 14.9 ± 2.6 | 28.2 ± 8.1 | 22.9 ± 3.7 | |
| RE AFTER EP | 25.5 ± 12 | 14.9 ± 2.6 | 29.5 ± 7.1 | 24.2 ± 3.6 | ||
FeAA—fraction of expired anaesthetic agent (sevoflurane), FiAA—fraction of inpired anaesthetic agent (sevoflurane), MAC—mean alveolar concentration of anaesthetic agent (sevoflurane), HR—heart rate, SAP—systolic arterial pressure, MAP—mean arterial pressure, DAP—diastolic arterial pressure, fEMG—facial electromyography, SE—state entropy, RE—response entropy. Results presented as means ± standard deviations and medians (interquartile ranges). a One-way analysis of variance (ANOVA). A Significantly higher in Group VCRII-nEP than in Group VIMA-EP (p < 0.01); B significantly higher in Group VIMA-EP than in Group VCRII-EP (p < 0.01); D significantly higher in Group VIMA-nEP than in Group VCRII-EP (p < 0.01); E significantly higher in Group VCRII-nEP than in Group VCRII-EP (p < 0.05).
Figure 1Medians with interquartile range (M (IQR)) of state entropy (SE) in groups: (A) volatile-vitalcap-EPI (VCRII-EP), (B) volatile-vitalcap-NOTEPI (VCRII-NEP), (C) (VIMA-EP), (D) (VIMA-NEP), on separate stages of the study, indicating a sequence of events (p-values: * <0.05, ** <0.01).
Figure 2Median values M (IQR) of response entropy (RE) in groups: (A) volatile-vitalcap-EPI (VCRII-EP), (B) volatile-vitalcap-NOTEPI (VCRII-NEP), (C) (VIMA-EP), (D) (VIMA-NEP), on separate stages of the study, indicating a sequence of events (p-values: * <0.05, ** <0.01).
Comparison of values of monitored patients’ parameters at the same stage between studied groups. (stage 1: before onset of VIGA, stage 2: after LOC, stage 3: before presence of first epileptiform pattern, stage 4: during presence of epileptiform patterns, stage 5: during the highest values of RE and RE during presence of epileptiform patterns in patients from group VIMA and VCRII, Stage 6: during the highest values of RE and RE after disappearance of epileptiform patterns in patients from group VIMA and VCRII).
| Induction | VIMA-EP | VCRII-EP | VIMA-nEP | VCRII-nEP | ||
|---|---|---|---|---|---|---|
| Level | Parameters | |||||
| STAGE 1 | HR START (beats/min) | 79.3±9.4 | 81.1 ± 17.3 | 66.2 ± 12.8 | 81.6 ± 17.5 | |
| SAP START (mmHg) | 151.1 ± 26 | 138.1 ± 11.7 | 143.2 ± 9.9 | 150.8 ± 36.1 | ||
| DAP START (mmHg) | 89.2 ± 15.1 | 70.5 ± 10.2 | 82.4 ± 3.3 | 85.6 ± 18.1 | ||
| MAP START (mmHg) | 113.7 ± 17.5 | 97.3 ± 9.1 | 104.9 ± 5.4 | 109.6 ± 24.1 | ||
| fEMG START | 7 ± 4.7 | 13.5 ± 11.6 | 7.3 ± 6.6 | 7.5 ± 4.8 | ||
| STAGE 2 | FeAA DURING LOC | 4.4 ± 1.4 | 3.8 ± 1.1 | 4.3 ± 1.5 | 4.8 ± 1.5 | |
| FiAA DURING LOC | 6.2 ± 1.7 | 6.9 ± 1.1 | 6.4 ± 1 | 7.5 ± 0.4 | ||
| MAC DURING LOC | 2.1 ± 0.7 | 1.8 ± 0.5 | 2.1 ± 0.7 | 2.3 ± 0.7 | ||
| HR DURING LOC (beats/min) | 84.9 ± 21.4 | 88 ± 17.2 | 77.3 ± 24 | 92.6 ± 22 | ||
| SAP DURING LOC (mmHg) | 158.7 ± 34 | 138.9 ± 11 | 150.4 ± 22.1 | 149.9 ± 37.5 | ||
| DAP DURING LOC (mmHg) | 86 ± 16.6 | 72.3 ± 9.7 | 86.9 ± 3.8 | 83.4 ± 17.4 | ||
| MAP DURING LOC (mmHg) | 113.4 ± 19.1 | 95.6 ± 17.3 | 112 ± 10.9 | 107.6 ± 21.5 | ||
| fEMG DURING LOC | 1.8 ± 1.5 | 15.4 ± 36.6 | 1.6 ± 1.4 | 1.3 ± 1 | ||
| STAGE 3 | FeAA BEFORE EP (%) | 5.1 ± 0.9 | 4.9 ± 1.4 | 5 ± 0.4 | 4.8 ± 0.9 | |
| FiAA BEFORE EP (%) | 6.6 ± 0.8 | 6.4 ± 0.9 | 6.5 ± 0.9 | 7.1 ± 0.8 | ||
| MAC BEFORE EP | 2.5 ± 0.4 | 2.4 ± 0.7 | 2.4 ± 0.2 | 2.3 ± 0.4 | ||
| HR BEFORE EP (beats/min) | 80.4 ± 17 | 91.1 ± 20.2 | 79.7 ± 19.8 | 87.9 ± 16.9 | ||
| SAP BEFORE EP (mmHg) | 137.2 ± 20.5 | 138.9 ± 11 | 140.7 ± 26.9 | 147.3 ± 40 | ||
| DAP BEFORE EP (mmHg) | 78.4 ± 16.8 | 72.8 ± 8.5 | 82.3 ± 11.7 | 81.2 ± 16.6 | ||
| MAP BEFORE EP (mmHg) | 102.8 ± 16.8 | 101.2 ± 6.6 | 105.3 ± 17.4 | 105.6 ± 22.9 | ||
| fEMG BEFORE EP | 1.2 ± 2.1 | 0.8 ± 0.6 | 0.8 ± 0.5 | 0.9 ± 1.2 | ||
| STAGE 4 | FeAA ONSET OF EP (%) | 4.6 ± 0.7 | 4.5 ± 0.9 | 5.7 ± 1.2 | 5 ± 1 | |
| FiAA ONSET OF EP (%) | 6.1 ± 0.9 | 6.8 ± 0.9 | 6 ± 1.5 | 6.8 ± 0.5 | ||
| MAC ONSET OF EP | 2.3 ± 0.3 | 2.2 ± 0.5 | 2.7 ± 0.7 | 2.4 ± 0.5 | ||
| HR ONSET OF EP (beats/min) | 81.9 ± 23 | 101 ± 32.2 | 78.5 ± 15.6 | 79.2 ± 18.8 | ||
| SAP ONSET OF EP (mmHg) | 135.9 ± 26.1 | 122.9 ± 25.7 | 129.5 ± 14.2 | 130.7 ± 27.8 | ||
| DAP ONSET OF EP (mmHg) | 80.2 ± 16.4 | 63.1 ± 13.4 | 80.7 ± 11.7 | 79.7 ± 17.4 | ||
| MAP ONSET OF EP (mmHg) | 101.1 ± 20.4 | 89.4 ± 18.4 | 97.1 ± 10.8 | 98.4 ± 19.7 | ||
| fEMG ONSET OF EP | 0.2 ± 0.1 | 0.6 ± 0.4 | 0.4 ± 0.6 | 0.3 ± 0.6 | ||
| STAGE 5 | FeAA DURING EP (%) | 4.4 ± 1.5 | 5.2 ± 1.5 | 5.6 ± 1.6 | 5.3 ± 1 | |
| FiAA DURING EP (%) | 5.7 ± 1.7 | 7 ± 0.8 | 6.1 ± 1.5 | 6.6 ± 0.6 | ||
| MAC DURING EP | 2.3 ± 0.7 | 2.6 ± 0.7 | 2.7 ± 0.8 | 2.6 ± 0.5 | ||
| HR DURING EP (beats/min) | 82.9 ± 20.1 | 87.9 ± 18.2 | 76.8 ± 12.7 | 77.4 ± 15.6 | ||
| SAP DURING EP (mmHg) | 132.9 ± 22.9 | 132.1 ± 13.3 | 126.7 ± 12.5 | 129.1 ± 34.2 | ||
| DAP DURING EP (mmHg) | 80.4 ± 17.3 | 68.1 ± 9.9 | 78.8 ± 11 | 75.3 ± 20.9 | ||
| MAP DURING EP (mmHg) | 101 ± 18.2 | 96.2 ± 9.6 | 95 ± 9 | 95.4 ± 23.4 | ||
| fEMG DURING EP | 0.3 ± 0.2 | 0.5 ± 0.4 | 0.3 ± 0.6 | 0.3 ± 0.3 | ||
| STAGE 6 | FeAA AFTER EP (%) | 4.1 ± 1.3 | 3.8 ± 1.1 | 4.7 ± 1 | 4.1 ± 0.9 | |
| FiAA AFTER EP (%) | 5 ± 1.6 | 5 ± 1.6 | 5.5 ± 1.1 | 4.6 ± 0.9 | ||
| MAC AFTER EP | 2 ± 0.6 | 1.9 ± 0.5 | 2.3 ± 0.5 | 2 ± 0.4 | ||
| HR AFTER EP (beats/min) | 82.5 ± 23.8 | 82.3 ± 20.8 | 67 ± 15.5 | 81.7 ± 17.1 | ||
| SAP AFTER EP (mmHg) | 139.8 ± 40.9 | 107.9 ± 19.4 | 104.1 ± 26.3 | 111.8 ± 20.4 | ||
| DAP AFTER EP (mmHg) | 81.6 ± 23.1 | 54.9 ± 10.8 | 64.9 ± 20.8 | 65.9 ± 13 | ||
| MAP AFTER EP (mmHg) | 104 ± 29.6 | 80.5 ± 14.4 | 80.3 ± 21.2 | 83.9 ± 13.8 | ||
| fEMG AFTER EP | 0.2 ± 0.1 | 0.2 ± 0.1 | 0.2 ± 0.2 | 0.1 ± 0.1 | ||
Legend: FeAA—fraction of expired anaesthetic agent (sevoflurane), FiAA—fraction of inpired anaesthetic agent (sevoflurane), MAC—mean alveolar concentration of anaesthetic agent (sevoflurane), HR—heart rate, SAP—systolic arterial pressure, MAP-mean arterial pressure, DAP—diastolic arterial pressure, fEMG—facial electromyography, SE—state entropy, RE-response entropy. Results presented as means ± standard deviations and medians (interquartile ranges). a 1-way analysis of variance (ANOVA). C Significantly higher in Group VIMA-EP than in Group VCRII-EP (p < 0.05).
Comparison of values of monitored patients’ parameters between different stages of volatile induction of general anaesthesia in studied groups of patients.
| Parameters | VIMA-EP | VCRII-EP | VIMA-nEP | VCRII-nEP | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage | Stage | Stage | Stage | ||||||||||||||
| 3 | 4 | 5 | 3 | 4 | 5 | 3 | 4 | 5 | 3 | 4 | 5 | ||||||
| SE | 26.1 ± 14.5 | 24 ± 11.7 | 30 ± 20.1 | 53.4 ± 39.1 | 46.9 ± 38.4 | 10.9 ± 3.3 | 61 ± 29.8 | 22.5 ± 6 | 27 ± 6.7 | 82.1 ± 9.6 | 15.1 ± 5.8 | 18.6 ± 5.6 | |||||
| RE | 30 ± 20 | 29 ± 16 | 35.9 ± 24.3 | 59.1 ± 44 | 53.4 ± 41.4 | 12.3 ± 3.5 | 67.2 ± 33.3 | 24.5 ± 5 | 29 ± 7 | 90 ± 10 | 17.7 ± 7.8 | 19.6 ± 6.4 | |||||
FeAA—fraction of expired anaesthetic agent (sevoflurane), FiAA—fraction of inspired anaesthetic agent (sevoflurane), MAC—mean alveolar concentration of anaesthetic agent (sevoflurane), HR—heart rate, SAP—systolic arterial pressure, MAP—mean arterial pressure, DAP—diastolic arterial pressure, fEMG—facial electromyography, SE—state entropy, RE—response entropy. Results presented as means ± standard deviations X ± SD and medians (interquartile ranges) M (IQR). a One-way analysis of variance (ANOVA) for repeated measures. b Two-way analysis of variance (ANOVA) for repeated measures: Stage × Group
Comparison of values of monitored patients’ parametres between different stages of volatile induction of general anaesthesia in studied groups of patients.
| Parameters | VIMA-EP | VCRII-EP | VIMA-nEP | VCRII-nEP | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stage | Stage | Stage | Stage | ||||||||||||||
| 3 | 4 | 5 | 3 | 4 | 5 | 3 | 4 | 5 | 3 | 4 | 5 | ||||||
| FeAA | 5.1 ± 0.9 | 4.6 ± 0.7 | 4.4 ± 1.5 | 4.9 ± 1.4 | 4.5 ± 0.9 | 5.2 ± 1.5 | 5 ± 0.4 | 5.7 ± 1.2 | 5.6 ± 1.6 | 4.8 ± 0.9 | 5 ± 1 | 5.3 ± 1 | |||||
| FiAA (%) | 6.6 ± 0.8 | 6.1 ± 0.9 | 5.7 ± 1.7 | 6.4 ± 0.9 | 6.8 ± 0.9 | 7 ± 0.8 | 6.5 ± 0.9 | 6 ± 1.5 | 6.1 ± 1.5 | 7.1 ± 0.8 | 6.8 ± 0.5 | 6.6 ± 0.6 | |||||
| MAC | 2.5 ± 0.4 | 2.3 ± 0.3 | 2.3 ± 0.7 | 2.4 ± 0.7 | 2.2 ± 0.5 | 2.6 ± 0.7 | 2.4 ± 0.2 | 2.7 ± 0.7 | 2.7 ± 0.8 | 2.3 ± 0.4 | 2.4 ± 0.5 | 2.6 ± 0.5 | |||||
| HR | 80.4 ± 17 | 81.9 ± 23 | 82.9 ± 20.1 | 91.1 ± 20.2 | 101 ± 32.2 | 87.9 ± 18.2 | 79.7 ± 19.8 | 78.5 ± 15.6 | 76.8 ± 12.7 | 87.9 ± 16.9 | 79.2 ± 18.8 | 77.4 ± 15.6 | |||||
| SAP (mmHg) | 137.2 ± 20.5 | 135.9 ± 26.1 | 132.9 ± 22.9 | 138.9 ± 11 | 122.9 ± 25.7 | 132.1 ± 13.3 | 140.7 ± 26.9 | 129.5 ± 14.2 | 126.7 ± 12.5 | 147.3 ± 40 | 130.7 ± 27.8 | 129.1 ± 34.2 | |||||
| DAP (mmHg) | 78.4 ± 16.8 | 80.2 ± 16.4 | 80.4 ± 17.3 | 72.8 ± 8.5 | 63.1 ± 13.4 | 68.1 ± 9.9 | 82.3 ± 11.7 | 80.7 ± 11.7 | 78.8 ± 11 | 81.2 ± 16.6 | 79.7 ± 17.4 | 75.3 ± 20.9 | |||||
| MAP (mmHg) | 102.8 ± 16.8 | 101.1 ± 20.4 | 101 ± 18.2 | 101.2 ± 6.6 | 89.4 ± 18.4 | 96.2 ± 9.6 | 105.3 ± 17.4 | 97.1 ± 10.8 | 95 ± 9 | 105.6 ± 22.9 | 98.4 ± 19.7 | 95.4 ± 23.4 | |||||
| fEMG | 1.2 ± 2.1 | 0.2 ± 0.1 | 0.3 ± 0.2 | 0.8 ± 0.6 | 0.6 ± 0.4 | 0.5 ± 0.4 | 0.8 ± 0.5 | 0.4 ± 0.6 | 0.3 ± 0.6 | 0.9 ± 1.2 | 0.3 ± 0.6 | 0.3 ± 0.3 | |||||
Legend: FeAA—fraction of expired anaesthetic agent (sevoflurane), FiAA—fraction of inpired anaesthetic agent (sevoflurane), MAC—mean alveolar concentration of anaesthetic agent (sevoflurane), HR—heart rate, SAP—systolic arterial pressure, MAP—mean arterial pressure, DAP – diastolic arterial pressure, fEMG – facial electromyography, SE—state entropy, RE—response entropy. Results presented as means ± standard deviations and medians (interquartile ranges). a. 1-way analysis of variance (ANOVA) for repeated measures b. 2-way analysis of variance (ANOVA) for repeated measures: Stage*Group.
Figure 3Number of erroneous (A) SE, (B) RE values at different stages of general anaesthesia. SE—state entropy, RE—response entropy. Results presented as numbers (percentages) for discrete variables.
The strength of the relationship between selected parameters. R’ Spearman’s correlation coefficient.
| Group | Parameter | SE | RE | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Stage | Stage | ||||||||
| 3 | 4 | 5 | 6 | 3 | 4 | 5 | 6 | ||
| VCRII-EP | FeAA | −0.16 | −0.46 | −0.27 | −0.54 | −0.11 | −0.43 | −0.2 | −0.54 |
| FiAA | −0.23 | 0.68 |
| −0.09 | −0.32 | 0.54 |
| −0.09 | |
| MAC | −0.16 | −0.46 | −0.27 | −0.54 | −0.11 | −0.43 | −0.2 | −0.54 | |
| HR | 0.56 |
| −0.75 | −0.68 | 0.54 | 0.89 | −0.65 | −0.68 | |
| SAP | 0.61 | 0.71 | −0.29 | 0.11 | 0.54 | 0.61 | −0.24 | 0.11 | |
| DAP | 0.09 | 0.61 | 0.07 | 0.2 | 0 | 0.5 | 0.05 | 0.2 | |
| MAP | 0.25 | 0.68 | −0.15 | 0.11 | 0.14 | 0.57 | −0.15 | 0.11 | |
| fEMG | −0.18 | −0.23 | 0.15 | −0.08 | −0.14 | −0.14 | 0.2 | −0.08 | |
| VCRII-nEP | FeAA | 0.25 | 0.3 | 0.46 | −0.58 | 0.34 | 0.46 | 0.3 | −0.34 |
| FiAA | −0.34 | −0.54 | −0.58 | −0.37 | −0.55 | −0.25 | −0.44 | −0.34 | |
| MAC | 0.25 | 0.33 | 0.46 | −0.59 | 0.34 | 0.46 | 0.3 | −0.36 | |
| HR |
| −0.19 | 0.43 | 0.09 | 0.52 | −0.05 | 0.53 | 0 | |
| SAP | −0.1 |
| −0.08 | −0.18 | −0.38 | −0.57 | −0.12 | 0.01 | |
| DAP | −0.08 |
| 0.22 | 0.05 | −0.29 | −0.69 | 0.12 | 0.17 | |
| MAP | −0.13 |
| −0.11 | −0.09 | −0.39 | −0.69 | −0.18 | 0.12 | |
| fEMG | 0.57 | 0.6 | 0.33 | 0.36 | 0.64 | 0.6 | 0.55 | 0.36 | |
| VIMA-EP | FeAA | −0.04 | −0.12 | −0.62 | −0.3 | −0.22 | −0.11 | −0.47 | −0.37 |
| FiAA | −0.14 | −0.38 | −0.57 | −0.33 | −0.04 | −0.44 | −0.43 | −0.36 | |
| MAC | −0.04 | 0.25 | −0.39 | −0.3 | −0.22 | 0.24 | −0.28 | −0.37 | |
| HR | −0.19 | 0.03 | −0.1 | −0.06 | −0.34 | 0.17 | 0.02 | 0.01 | |
| SAP | −0.07 | −0.37 | −0.27 | −0.13 | 0.05 | −0.52 | −0.5 | −0.21 | |
| DAP | −0.53 | −0.16 | −0.1 | −0.24 | −0.35 | −0.3 | −0.37 | −0.32 | |
| MAP | −0.09 | −0.2 | −0.1 | −0.2 | 0.09 | −0.35 | −0.32 | −0.27 | |
| fEMG | 0.06 | −0.03 | −0.11 | −0.15 | 0.21 | 0.07 | 0.06 | −0.19 | |
| VIMA-nEP | FeAA | 0.37 | −0.03 | −0.2 | −0.67 | 0.46 | 0.06 | −0.03 | −0.71 |
| FiAA | −0.6 | 0.46 | −0.61 | −0.38 | −0.49 | 0.17 | −0.49 | −0.49 | |
| MAC | 0.37 | 0.26 | −0.2 | −0.67 | 0.46 | −0.06 | −0.03 | −0.71 | |
| HR | 0.26 | 0.29 | 0.43 | −0.26 | 0.14 | −0.23 | 0.67 | −0.29 | |
| SAP | −0.2 | −0.32 | −0.17 | −0.81 | −0.12 | −0.17 | −0.23 | −0.77 | |
| DAP | −0.37 | −0.32 | −0.03 |
| −0.35 | −0.75 | 0.14 |
| |
| MAP | −0.2 | −0.49 | 0.12 |
| −0.12 | −0.41 | 0.23 |
| |
| fEMG | 0.35 | −0.28 | 0.02 | −0.05 | 0.35 | −0.92 | 0.14 | −0.17 | |
a One-way analysis of variance (ANOVA).
Number of erroneous SE values including number of epileptiform patterns at different stages in groups with symptoms of epilepsy.
| Parameter | Stage 4 | Stage 5 | Stage 6 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SE | Polispykes (PS) | Periodic | Polyspikes (PS) and | Periodic | Polyspikes (PS) and | Periodic | |||||||||
| VCRII-EP | VIMA-EP | Total | VIMA-EP | VCRII-EP | VIMA-EP | Total | VIMA-EP | VCRII-EP | VIMA-EP | Total | VIMA-EP | ||||
| deep anesthesia | 3 | 4 | 7 | 3 | 7 | 3 | 10 | 3 | 7 | 4 | 11 | 4 | |||
| (0.30) | 42.9% | 80.0% | 58.3% | 60% | 100.0% | 60.0% | 83.3% | 60% | 100% | 80% | 91.7% | 80% | |||
| strong anesthesia | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | |||
| <30.40) | 14.3% | 0.0% | 8.3% | 20% | 0.0% | 20.0% | 8.3% | 20% | 0% | 0% | 0% | 20% | |||
| Norm | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 0 | |||
| <40.60) | 0.0% | 20.0% | 8.3% | 20% | 0.0% | 0.0% | 0.0% | 20% | 0% | 20% | 8.3% | 0% | |||
| possible recovery | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| <60.80) | 0.0% | 0.0% | 0.0% | 0% | 0.0% | 0.0% | 0.0% | 0% | 0% | 0% | 0% | 0% | |||
| recovery | 3 | 0 | 3 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | |||
| <80.100) | 42.9% | 0.0% | 25.0% | 0% | 0.0% | 20.0% | 8.3% | 0% | 0% | 0% | 0% | 0% | |||
Results presented as numbers (percentages) for discrete variables. a the Fisher’s Exact Test.
Figure 4Epileptiform activity during increase in RE and SE values at fifth stage of VIGA with sevoflurane using VIMA technique.
Figure 5Epileptiform activity during the lowest values of RE and SE at fifth stage of VIGA with sevoflurane using VIMA technique.